Last $9.12 USD
Change Today +0.12 / 1.33%
Volume 10.6K
RXDX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

ignyta inc (RXDX) Snapshot

Open
$8.96
Previous Close
$9.00
Day High
$9.36
Day Low
$8.90
52 Week High
01/29/14 - $20.00
52 Week Low
12/20/13 - $1.00
Market Cap
178.6M
Average Volume 10 Days
41.0K
EPS TTM
--
Shares Outstanding
19.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IGNYTA INC (RXDX)

Related News

No related news articles were found.

ignyta inc (RXDX) Related Businessweek News

No Related Businessweek News Found

ignyta inc (RXDX) Details

Ignyta, Inc., a precision medicine biotechnology company, is engaged in discovering or acquiring, developing, and commercializing new drugs for cancer patients. Its products pipeline consists of RXDX-101, a tyrosine kinase inhibitor directed to the Trk family tyrosine kinase receptors, ROS1, and ALK proteins, which is in a Phase I/II clinical study in molecularly defined patient populations for the treatment of solid tumors; and RXDX-102, a tyrosine kinase inhibitor directed to the Trk family tyrosine kinase receptors. The company was founded in 2011 and is based in San Diego, California.

23 Employees
Last Reported Date: 05/14/14
Founded in 2011

ignyta inc (RXDX) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $437.5K
Chief Operating Officer
Total Annual Compensation: $305.0K
Compensation as of Fiscal Year 2013.

ignyta inc (RXDX) Key Developments

Ignyta Announces Interim Data from RXDX-101 Phase I Clinical Trial

Ignyta, Inc. announced that interim results from the first-in-human ALKA-372-001 Phase I clinical trial of RXDX-101, the company's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, were presented in an oral presentation at the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois. The dose escalation study was designed to determine the maximum tolerated dose (MTD) and recommended Phase II dose, as well as preliminary anti-cancer activity of single agent RXDX-101 in patients with solid tumors with molecular alterations in the TrkA, ROS1 or ALK tyrosine kinase receptors. For each of the first three weeks of each 28-day dosing cycle, patients received RXDX-101 for four consecutive days, followed by three days without dosing. During the fourth week of each such dosing cycle, patients were not dosed. The doses tested to date are 100, 200, 400, 800, 1,200 and 1,600 mg/m(2) per day.

Ignyta, Inc. Announces Executive Changes

Ignyta, Inc. announced that Jacob Chacko, M.D. has been appointed as Chief Financial Officer, assuming responsibility for the role from Zachary Hornby, who has been appointed to the newly-created role of Chief Operating Officer. Dr. Chacko joins Ignyta from TPG Capital where he served as a Vice President focused primarily on healthcare and digital media since August 2008.

Ignyta, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014

Ignyta, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the year, the company reported loss from operations of $3,939,000 compared to $1,012,000 a year ago. Loss before income tax was $4,102,000 compared to $1,013,000 a year ago. Net loss was $4,107,000 or $0.28 per basic and diluted share compared to $1,015,000 or $1.55 per basic and diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RXDX:US $9.12 USD +0.12

RXDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RXDX.
View Industry Companies
 

Industry Analysis

RXDX

Industry Average

Valuation RXDX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IGNYTA INC, please visit www.ignyta.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.